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Background: In patients with type 2 diabetes mellitus (T2DM), hypertension and microalbuminuria are predictive
markers for increased renal and cardiovascular risk. This post hoc analysis of data from a global development
program aimed to evaluate the efficacy and safety of linagliptin in a population with joint prevalence of these two
vascular risk factors.
Methods: Data for patients with baseline microalbuminuria (urine albumin-to-creatinine ratio 30–300 mg/g) and
hypertension (systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg and/or a history of
hypertension; and/or an antihypertensive treatment at baseline) who participated in any of six randomized,
placebo-controlled, phase III trials were analyzed. Participants received linagliptin 5 mg daily (alone or in
combination with other oral antidiabetic drugs) or placebo for 18 to 24 weeks.
Results: Of 3,119 patients, 512 had both microalbuminuria and hypertension (linagliptin, 366; placebo, 146).
Baseline mean (SD) HbA1c was 8.3 (0.9)% and 8.4 (0.9)%; median (range) urine albumin-to-creatinine ratio was
60 (30–292) mg/g and 64 (30–298) mg/g; mean (SD) systolic blood pressure was 138 (15) mm Hg and 135 (16)
mm Hg; and mean (SD) diastolic blood pressure was 81 (10) mm Hg and 81 (10) mm Hg, for linagliptin and placebo,
respectively. Placebo-corrected mean change in HbA1c from baseline to week 18 and week 24 was −0.57%
(95% CI: −0.75, −0.39; P < 0.0001) and −0.59% (95% CI: −0.80, −0.39; P < 0.0001), respectively. Placebo-corrected mean
change in FPG from baseline to week 24 was −21.3 mg/dl (95% CI: −31.0, −11.6; P < 0.0001). The incidence of drug-
related adverse events was similar for linagliptin and placebo (10.4% and 8.2%, respectively). Changes in systolic and
diastolic blood pressure, cholesterol and triglyceride levels were similar between linagliptin and placebo.
Conclusion: In T2DM patients with the two common vascular risk factors of hypertension and microalbuminuria,
linagliptin achieved significant improvements in glycemic control. In this vulnerable patient population at high risk for
micro- and macrovascular complications, linagliptin was well tolerated.
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Type 2 diabetes mellitus (T2DM) affects over 300 mil-
lion people worldwide and is the leading cause of renal
and cardiovascular complications [1]. Despite lifestyle
and pharmaceutical interventions, the management of
hyperglycemia in patients at risk for renal and cardiovas-
cular complications remains an important challenge to
physicians treating this population [2]. In patients with
T2DM and hypertension, urinary albumin is a key prog-
nosticator of both renal and cardiovascular outcomes,
with even low levels of albuminuria being associated with
progressive renal dysfunction and increased risk of cardio-
vascular mortality [3]. Furthermore, traditional risk factors
for atherosclerotic kidney disease, such as diabetes and
hypertension, can lead to a cycle of declining renal func-
tion and progressive atherosclerosis (Figure 1) [4]. For
these reasons, guidelines for the treatment of T2DM rec-
ommend testing for the presence of microalbuminuria –
an early indicator of renal dysfunction – at initial diagnosis
and in annual follow-up visits [5,6].
Linagliptin is an oral, once-daily dipeptidyl peptidase
(DPP)-4 inhibitor that prevents the inactivation of
incretin hormones glucagon-like peptide (GLP)-1 and
glucose-dependent insulinotropic peptide, which stimu-
late glucose-dependent secretion of insulin. In large clin-
ical trials undertaken in patients with T2DM, linagliptin
as monotherapy or in combination with other oral
antidiabetic drugs (OADs) has shown clinically meaning-
ful efficacy with a low risk of hypoglycemia and no
weight gain [7-9]. A meta-analysis of linagliptin phase III
studies showed no increased cardiovascular risk with
linagliptin [10]. A pooled analysis of data from eight
phase III studies with linagliptin provided additionalFigure 1 Cardiovascular risk factors and progression of renal
dysfunction. *Diabetes, dyslipidemia, hypertension, obesity and
metabolic syndrome. CV, cardiovascular Adapted from Chade AR,
et al. Hypertension 2005;45:1042–1049.confirmation that linagliptin is well tolerated in patients
with or without renal dysfunction [11]. Although renal
dysfunction can increase risk for hypoglycemia, inci-
dence of hypoglycemic events in patients receiving
linagliptin without concomitant sulfonylurea was < 1.0%
in this high-risk population [11].
Many OADs are primarily eliminated via the kidney,
and require dosage adjustment based on renal function
monitoring or become contraindicated when renal func-
tion declines further. Linagliptin has a primarily non-
renal route of excretion. It can, therefore, be used
without dosage adjustment irrespective of renal function
[12], suggesting it is worthy of investigation in patients
with, or at high risk of developing, renal as well as car-
diovascular disease.
To further explore the effects of linagliptin in this
high-risk population, data from patients with hyperten-
sion and microalbuminuria from six phase III clinical
trials were pooled and analyzed.
Methods
This post hoc analysis pooled patient data from six ran-
domized, double-blind, placebo-controlled, phase III tri-
als from the linagliptin clinical trial program. These
trials, ranging from 18 to 24 weeks (one 18-week trial
included a 34-week active-controlled extension), were
selected from those listed in the approved United States
Food and Drug Administration prescribing information
(indicated as an adjunct to diet and exercise to improve
glycemic control in adults with T2DM) [12]. Patients
with T2DM were treated with linagliptin 5 mg once daily
or placebo as either monotherapy [7,13], add-on to met-
formin [9], add-on to sulfonylurea [14], add-on to met-
formin and a sulfonylurea [8], or as initial combination
with pioglitazone [15]. All but one study comprised a
4-week washout period for those subjects taking non-
protocol OADs, followed by a 2-week run-in period
(Figure 2). In the study evaluating linagliptin added to
metformin and a sulfonylurea, all patients directly en-
tered the 2-week run-in period [8]. Following placebo
run-in, patients were randomized to receive double-
blind linagliptin 5 mg or placebo once daily.
All protocols were approved by relevant local independ-
ent ethical review or institutional review committees. Tri-
als were carried out according to either the Declaration of
Helsinki or International Conference on Harmonization
Guideline for Good Clinical Practice. All patients provided
written informed consent before participation.
Patients were included in this analysis if they had
prevalent microalbuminuria (urine albumin-to-creatinine
ratio [UACR] 30–300 mg/g, determined after randomi-
zation and prior to first drug intake by spot urine-
quantitative measurement) and hypertension (systolic
blood pressure [SBP] ≥ 140 mm Hg and/or diastolic
Figure 2 Schematic diagram of study designs. *No washout was performed in the studies adding linagliptin to existing treatment with
metformin or sulfonylurea or both. Complementary study designs allowed pooling of the data.
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hypertension; and/or antihypertensive treatment at base-
line). The inclusion criteria for age and body mass index
(BMI) were similar in the six trials: age of ≥ 18 and ≤ 80 -
years and BMI of ≤ 40 kg/m2. The inclusion criteria for
glycated hemoglobin (HbA1c) levels at the start of placebo
run-in ranged between ≥ 7% and ≤ 11%. In the majority of
studies, OAD regimens, if any, needed to have remained
constant for ≥ 10 weeks prior to enrolment [7-9,14].
Efficacy was assessed by the change from baseline in
HbA1c and fasting plasma glucose (FPG) at 18 and 24 -
weeks of treatment. The analysis at week 18 was based on
data from all six clinical trials, whereas the analysis at week
24 was based on data from four clinical trials [7-9,15].
This was also true for the UACR and blood pressure
analyses of change from baseline. Lipid and blood pres-
sure analyses were based on the last value on treatment
(LVOT) data. Safety endpoints included the frequency
and intensity of adverse events (AEs) and the frequency
of hypoglycemic events.
Statistical analysis
Efficacy endpoints were evaluated with an analysis of co-
variance (ANCOVA). The general model contained the
following factors: treatment, washout of prior OAD and
study, as well as the linear covariate continuous baseline
HbA1c. For the FPG analysis, continuous baseline FPG
was also included in the general model. The efficacy
endpoints were assessed on the full analysis set (FAS),
comprising all randomized subjects who received ≥ 1
dose of study drug and had both baseline and ≥ 1 on-
treatment HbA1c measurement. A last observation
carried forward (LOCF) approach was used to handle
missing values for the calculation of the placebo-
corrected mean change in HbA1c at week 18 and week
24 and the placebo-corrected mean change in FPG at
week 24. The placebo-corrected mean change in FPG at
week 18 was presented as observed cases (OC) because
LOCF data were not available from all included trials forthat time point. Efficacy measurements after start of res-
cue were replaced by missing values. Pooled safety data
were recorded from the treated set (all randomized sub-
jects who received ≥ 1 dose of study drug) and were ana-
lyzed using descriptive statistics.
Results
Patient demographics
Across the six studies, 3,119 patients were treated with
either linagliptin 5 mg once daily (2,222) or placebo
(897). Among that population, 512 patients were identi-
fied as having both microalbuminuria and hypertension
at baseline and were therefore eligible for inclusion in
the pooled analysis. At baseline, patient demographics
and clinical characteristic were similar in the linagliptin
and placebo groups (Table 1). In the overall evaluated
population patients had a mean age of 59.5 years, with
mean BMI of 29.9 kg/m2. Baseline mean (SD) HbA1c
and FPG were similar in both treatment groups (HbA1c:
linagliptin, 8.3 [0.9]% and placebo, 8.4 [0.9]%; FPG:
linagliptin, 176 [52] mg/dl and placebo, 178 [39] mg/dl).
At baseline, the majority of patients were being treated
with two OADs (48.6%) and had known diabetes for >
5 years (57.6%). The median (range) UACR at baseline
was 60 (30–292) mg/g for linagliptin and 64 (30–298)
mg/g for placebo. The mean (SD) SBP was 138 (15) mm
Hg and 135 (16) mm Hg, and mean (SD) DBP was 81
(10) mm Hg and 81 (10) mm Hg for linagliptin and pla-
cebo, respectively.
Antihypertensive therapy was taken by 86.3% and
84.9% of patients in the linagliptin and placebo groups,
respectively. The most commonly reported antihyperten-
sive drugs were angiotensin-converting enzyme (ACE)
inhibitors (linagliptin, 40.4% and placebo, 41.1%).
Efficacy
Among patients with microalbuminuria and hypertension,
those treated with linagliptin achieved a significantly
greater reduction in HbA1c from baseline compared with
Table 1 Baseline patient demographics and clinical characteristics (treated set)




Age, years 59.8 (10.2) 58.8 (9.8)
Male, % 50.0 58.2
Race, %
American Indian/Alaska Native 0.5 0.7
Asian 36.3 34.9
Black/African American 1.6 1.4
White 61.5 63.0
HbA1c, % 8.3 (0.9) 8.4 (0.9)
FPG, mg/dl* 176 (52) 178 (39)
BMI, kg/m2 29.9 (5.1) 29.9 (4.9)
eGFR, %
≥ 90 ml/min 50.5 54.8
60 to < 90 ml/min 41.5 38.4
30 to < 60 ml/min 7.9 6.8
Urine albumin-to-creatinine ratio, mg/g, median (range)† 60 (30–292) 64 (30–298)
SBP, mm Hg 138 (15) 135 (16)
DBP, mm Hg 81 (10) 81 (10)
Metabolic syndrome, % 64.8 60.3
Time since diagnosis of diabetes, %
Up to 1 year 11.2 13.7
> 1 to 5 years 29.5 32.9
> 5 years 59.3 53.4





Antihypertensive therapy, % 86.3 84.9
Beta-blockers 29.8 23.3
ACE inhibitors 40.4 41.1
ARBs 21.0 19.9
Diuretics 19.1 21.2
Calcium antagonists 27.6 27.4
Combinations 13.4 13.7
*Linagliptin, n = 358; placebo, n = 144.
†Linagliptin, n = 348; placebo, n = 138.
eGFR, estimated glomerular filtration rate, according to the Modification of Diet in Renal Disease study equation; ACE, angiotensin-converting enzyme; ARB,
angiotensin-II receptor blocker.
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line (SE) in HbA1c at week 18 was −0.57 (0.06)% for
linagliptin and 0.0 (0.08)% for placebo, resulting in a
placebo-corrected mean change from baseline in HbA1c
of −0.57% (95% confidence interval [CI]: −0.75, −0.39;
P < 0.0001). At week 24, the adjusted mean change from
baseline in HbA1c was −0.65 (0.06)% and −0.05 (0.09)% inthe linagliptin and placebo groups, respectively. In these
patients, the placebo-corrected mean change from base-
line in HbA1c was −0.59% (95% CI: −0.80, −0.39;
P < 0.0001) at week 24.
Linagliptin was also better than placebo in lowering
FPG levels in this population. Adjusted mean change
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Figure 3 Change from baseline in HbA1c at week 18 (A)* and
week 24 (B)† (FAS LOCF). *Data based on all six clinical trials.
†Data based on four clinical trials.
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resulting in a placebo-corrected mean change from base-
line of −10.6 mg/dl (95% CI: −18.4, −2.9; P = 0.0074). At
week 24, the adjusted mean change from baseline in FPG
was −13.4 (2.9) mg/dl and 7.9 (4.4) mg/dl in the linagliptin
and placebo groups, respectively. The placebo-corrected
mean change from baseline in these patients was
−21.3 mg/dl (95% CI: −31.0, −11.6; P < 0.0001).
Safety and tolerability
In the treated set, the overall incidences of any AE and
serious AEs were comparable between both treatment
groups (linagliptin, 62.6% and placebo, 62.3%; linagliptin,
4.1% and placebo, 6.2%). Investigator-determined drug-
related AEs were reported by 10.4% and 8.2% of the
linagliptin and placebo groups, respectively.
AEs leading to discontinuation of trial medication were
reported by 1.4% and 3.4% of patients in the linagliptin
and placebo groups, respectively. Less than 1% of subjects
experienced hypoglycemia when linagliptin was adminis-tered as monotherapy or in addition to metformin or
pioglitazone. However, when linagliptin was administered
with a sulfonylurea, the number of patients experiencing
hypoglycemia was greater than with placebo (linagliptin,
19.8% and placebo, 5.9%).
The median (range) change in UACR from baseline at
week 24 was −13.7 (−240.4 to 695.7) mg/g for linagliptin
and −4.9 (−234.3 to 2,263.9) mg/g for placebo. The
placebo-corrected median change from baseline in
UACR at week 24 was −8.8 mg/g.
Mean (SD) SBP decreased by −2.9 (0.9) mm Hg and
−2.4 (1.2) mm Hg in the linagliptin and placebo groups,
respectively, at LVOT (Table 2). Mean (SD) DBP de-
creased by −1.2 (0.6) mm Hg and −1.0 (0.8) mm Hg in the
linagliptin and placebo groups, respectively, at LVOT.
Minor changes were observed in lipid parameters in
the linagliptin group as compared to the placebo group
(Table 2). Total cholesterol, low-density lipoprotein
and high-density lipoprotein showed small but non-
significant differences between the groups. Triglyceride
levels decreased in both treatment groups, with a
numerically greater decrease seen with linagliptin
(−18.5 mg/dl vs. −13.5 mg/dl).
No deaths occurred in either treatment group of the
population of patients with microalbuminuria and
hypertension. The incidence of the composite endpoint
of adjudicated cardiovascular death, myocardial infarc-
tion and stroke was 0.27% (n = 1) and 0.68% (n = 1) in
the linagliptin and placebo groups, respectively. A list of
AEs by system-organ class is presented in Table 3.
Discussion
Vascular complications are the main challenge in the man-
agement of T2DM. In patients with T2DM, hypertension
and prevalent microalbuminuria are common clinical fea-
tures that guide treating physicians in assessing risk of car-
diovascular and renal outcomes. Clinical evidence has
shown a clear transitional path from microalbuminuria to
chronic kidney disease [16] and a continuous relationship
between albuminuria of any degree and increased cardio-
vascular mortality [17,18].
In the United Kingdom Prospective Diabetes Study, one
quarter of patients developed microalbuminuria within
10 years of being diagnosed with T2DM [16]. Manifesta-
tions of urinary albumin progressed from normoal-
buminuria to microalbuminuria at an annual rate of 2.0%,
from microalbuminuria to macroalbuminuria at 2.8%
annually, and from macroalbuminuria to diabetic ne-
phropathy at 2.3% annually. Among patients with
microalbuminuria, the study found an annual cardiovascu-
lar mortality rate of 2.0% compared with 3.5% in those
with macroalbuminuria.
International guidelines for the treatment of T2DM
recommend reducing the risk or slowing the progression
Table 2 Adjusted mean change* from baseline to last value on treatment in total cholesterol, LDL cholesterol, HDL
cholesterol, and triglycerides
Linagliptin 5 mg (n = 366†) Placebo (n = 146†)
Mean (SE) Mean (SE)
Total cholesterol, mg/dl Baseline 180.4 (1.1) 177.2 (1.6)
Change from baseline −0.4 (1.0) 2.1 (1.3)
Placebo-corrected difference −1.8 (1.4) —
95% CI −4.4, 0.9 —
P value 0.195 —
LDL, mg/dl Baseline 144.5 (1.9) 142.3 (2.9)
Change from baseline 2.2 (1.8) 4.1 (2.3)
Placebo-corrected difference −1.8 (2.4) —
95% CI −6.6, 3.0 —
P value 0.452 —
HDL, mg/dl Baseline 40.2 (1.1) 40.0 (1.9)
Change from baseline 1.5 (0.6) 2.6 (0.8)
Placebo-corrected difference −1.2 (0.8) —
95% CI −2.8, 0.5 —
P value 0.172 —
Triglycerides, mg/dl Baseline 272.6 (12.5) 241.0 (10.1)
Change from baseline −18.5 (7.7) −13.5 (9.9)
Placebo-corrected difference −5.0 (10.6) —
95% CI −25.9, 15.9 —
P value 0.6360 —
SBP, mm Hg Baseline 137.8 (0.8) 134.8 (1.3)
Change from baseline −2.9 (0.9) −2.4 (1.2)
Placebo-corrected difference −0.6 (1.3) —
95% CI −3.1, 2.0 —
P value 0.664 —
DBP, mm Hg Baseline 80.5 (0.5) 81.4 (0.8)
Change from baseline −1.2 (0.6) −1.0 (0.8)
Placebo-corrected difference −0.2 (0.8) —
95% CI −1.9, 1.4 —
P value 0.773 —
*Adjusted for baseline HbA1c, parameter measured, prior OADs, study and treatment.
†Patient numbers varied for each parameter. For linagliptin, total cholesterol n = 351, LDL n = 349, HDL n = 348, triglycerides n = 349, SBP n = 359, DBP n = 359. For
placebo, total cholesterol n = 140, LDL n = 139, HDL n = 140, triglycerides n = 139, SBP n = 144, DBP n = 144.
DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LVOT, last value on treatment; SBP, systolic blood pressure.
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control [19]. A variety of pharmaceutical options for re-
duction of hyperglycemia are available, including metfor-
min, sulfonylureas and incretin-based therapies (GLP-1
analogs and DPP-4 inhibitors). For patients with T2DM,
however, renal impairment can be a limiting factor in
the selection of appropriate antihyperglycemic therapies.
Metformin and some sulfonylureas have contraindica-
tions or recommended dose adjustments related to renal
impairment. Dose adjustment is also recommended for
all DPP-4 inhibitors except linagliptin when used inpatients with moderate to severe renal impairment
[12,20]. Linagliptin, due to its predominantly non-renal
route of elimination, requires no dose adjustment.
In this post hoc analysis of 512 patients with T2DM
at high renal and vascular risk (defined as prevalent
hypertension and microalbuminuria with T2DM),
linagliptin showed significant and clinically relevant
reductions in HbA1c and FPG in comparison with
placebo. These findings were comparable to the effi-
cacy results found in the individual six phase III trials
[7-9,13-15].
Table 3 Summary of clinical AEs and hypoglycemia (treated set)





Any AE 62.6 62.3
Investigator-defined drug-related AE 10.4 8.2
Any AEs classified by system organ class*
Gastrointestinal disorders 11.5 15.8
Infections and infestations 21.6 22.6
Nasopharyngitis 5.7 4.8
Injury, poisoning and procedural complications 7.4 8.2
Metabolism and nutrition disorders 21.0 20.5
Musculoskeletal and connective tissue disorders 11.2 11.0
Nervous system disorders 8.2 12.3
Respiratory, thoracic and mediastinal disorders 4.6 5.5
Vascular disorders† 7.1 4.8
AEs leading to study drug discontinuation 1.4 3.4
Serious AEs 4.1 6.2
Deaths 0.0 0.0
Hypoglycemia
Subjects with hypoglycemia 9.3 2.1
Subjects with hypoglycemia by study
Studies without sulfonylurea‡ 0.5 0.0
Studies with sulfonylurea§ 19.8 5.9
Severe hypoglycemia¶ 0.3 0.0
*Medical Dictionary for Regulatory Activities, version 14.0.
†Individual AEs (preferred terms; %) were accelerated hypertension (linagliptin 0.0, placebo 0.7), arteriosclerosis (linagliptin 0.5, placebo 0.0), hypertension
(linagliptin 5.2, placebo 4.1), hypertensive crisis (linagliptin 1.1, placebo 0.0), temporal arteritis (linagliptin 0.3, placebo 0.0). 2 of these events were considered
drug-related (2 cases of hypertension; 1 with linagliptin and 1 with placebo).
‡Linagliptin, n = 199; placebo, n = 95.
§Linagliptin, n = 167; placebo, n = 51.
¶Event requiring assistance of another person to actively administer carbohydrate, glucagon or other resuscitation.
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that linagliptin was well tolerated. At baseline, patients
in the two treatment groups had well-matched clinical
characteristics and similar backgrounds of antihyperten-
sive therapies, with approximately 85% of each group re-
ceiving at least one drug in that class and 13% of each
group receiving combination antihypertensive therapy.
The incidence of hypoglycemia was markedly greater in
the linagliptin group only when linagliptin was adminis-
tered with sulfonylurea, which is consistent with clinical
findings for other DPP-4 inhibitors [8,21,22]. This ten-
dency may be attributable to the proposed uncoupling
effect that sulfonylureas have on the glucose-dependent
effects of incretin therapies [23]. The percentage of pa-
tients receiving linagliptin who experienced serious AEs
or AEs related to study drug was similar to those receiv-
ing placebo. Gastrointestinal AEs and infections, which
are of concern in the DPP-4 class, occurred in similarproportions of patients in the linagliptin and placebo
groups. No deaths occurred in either group.
Research suggests that GLP-1 may have beneficial
effects on dyslipidemia, and recent small studies with
DPP-4 inhibitors have shown favorable effects [24,25] or a
neutral effect [26] on postprandial dyslipidemia in patients
with T2DM. The present analysis showed a reduction in
mean triglyceride levels with linagliptin at LVOT, which
was numerically greater than that seen with placebo.
Linagliptin had a modest effect on blood pressure,
comparable to studies with other DPP-4 inhibitors, which
have shown small to neutral effects on blood pressure
[24,26-28]. Minor changes were also observed in UACR
with linagliptin treatment. In a recent post-hoc analysis of
pooled Phase III data, linagliptin significantly reduced
UACR after 24 weeks compared with placebo [29]. The
change in mean UACR versus baseline was −32% (95%
CI: −42, −21; P < 0.05) with linagliptin. Patients in this
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ging from micro- (UACR, >30 to ≤300 mg/g) to
macroalbuminuria (UACR >300 to ≤3000 mg/g) and were
on stable ACE inhibitor/angiotensin II receptor blocker
background therapy. Hence, differences in baseline UACR
levels along with more frequent concomitant treatment
with renin–angiotensin–aldosterone system inhibitors
may have contributed to the larger reduction in UACR in
that analysis. In order to specifically evaluate the albumin-
lowering potential of linagliptin a randomized, control-
led trial has recently been initiated (clinicaltrials.gov:
NCT01792518, MARLINA). So far, however, research on
the use of DPP-4 inhibitors in patients with renal dysfunc-
tion or albuminuria has been limited. The present analysis
did not evaluate the efficacy or safety of linagliptin by
subgroups of renal function, but baseline eGFR data were
included to provide a full description of the clinical char-
acteristics of the population with both microalbuminuria
and hypertension. DPP-4 inhibitors have previously been
shown to be efficacious and well tolerated at reduced
doses in patients with moderate to severe renal impair-
ment [30,31]. In clinical trial populations that included
patients with mild and moderate renal impairment,
linagliptin has been shown to be an efficacious and well-
tolerated treatment without dose adjustment [7,9,15]. A
phase I clinical trial with linagliptin showed that renal im-
pairment ranging from mild to end-stage renal disease
had no clinically meaningful effects on its pharmacokinet-
ics [32]. Additionally, a recently published phase III trial of
patients with severe renal impairment, demonstrated that
treatment with linagliptin 5 mg daily provided clinically
meaningful reductions in HbA1c over 1 year (−0.7%, 95%
CI: −21.0 to −20.4; P < 0.0001) with similar tolerability to
placebo [33].
In patients treated with linagliptin in the present ana-
lysis, incidence of severe hypoglycemia was very low,
body weight and renal function remained stable, and no
cases of drug-related renal failure were reported, sugges-
ting that linagliptin can be used safely in all patients and
even in this highly susceptible patient population with
severe renal impairment.
The findings of this study are limited by the post hoc
pooled nature of the analysis. Patients who participated
in any of six randomized, placebo-controlled, phase III
trials, had different background antidiabetic therapies.
The analysis was also based on a relatively short dur-
ation of 24 weeks or less, which does not allow for long-
term safety assessments. However, taken together with
previous reports of up to 2 years in patients with T2DM
[7-9,13-15,34], these results provide further evidence of
beneficial glycemic effects and tolerability in this popula-
tion. The ongoing CAROLINA trial (clinicaltrials.gov:
NCT01243424) is investigating long-term cardiovascular
outcomes with linagliptin. This trial will include patientswith vascular-related end-organ damage (such as mode-
rate renal dysfunction or microalbuminuria) as well as
patients with prevalent cardiovascular risk factors, such
as hypercholesterolemia or hypertension, and will allow
for long-term safety assessments. It is the first long-term,
clinical evaluation of a DPP-4 with an active comparator.
In conclusion, in patients with T2DM complicated by
hypertension and microalbuminuria, linagliptin 5 mg
once daily is well tolerated and improves glycemic con-
trol. Linagliptin may support long-term metabolic thera-
peutic strategies to treat patients at high risk of renal
and cardiovascular disease.
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